I have to laugh at all you retail shorts and naysayers. I and other tried to tell you is was a small hiccup and the hold would be lifted very soon. There simply isn't better options for these patients and the fact is this treatment along with other CarT therapy is highly effective.
wow that's a seriously uninformed post you just made. You do realize fludarabine is a common drug for CLL and also frequently used for conditioning ASCT. combined with Cyclophosphamide is often the conditioning regiment to prime the immune system for transplants. You need to get rid of the suppressor Tregs and make room for transplants to take. Same as the case for CART although you can use cy along rather Flu-Cy as they will no doubt do from now on with this construct.
If there were any doubt left IMPRESS has hammered the final nail into this coffin. Cancer Vaccines are dead end of story. You simply can not give a vaccine regardless of the form and expect T cell clonal expansion to any significant amount. Not to mention Pancreatic cancer is relatively antigenically silent. There's a reason why vaccines have only worked (minimally) in the most antigenic tumors i.e. melanoma.
Flu-cy is common conditioning regiment for ASCT and is logical for CART. It seems however it may prove to good of a conditioning regiment for this construct. iMO this will prove to be a non event. Flu-cy will be the standard conditioning regiment once the management of CSR is better understood.
yes conditioning is required to maximize the proliferation of the autologous Tcells but you can use a milder conditioning such as cyclophosphamide alone. You don't always need the most aggressive and often difficult to handle flu-cy.
Check point inhibitors work because they don't rely on T cell clonal expansion. Fundamentally the immune system wants to fight the cancer but the cancer has learned to evade this by over expressing the T cell co receptor PDL1 which puts the brakes on. Check point inhibitors releases this brake.
THis is a non event. Its all related to their attempt to add fludarabine as others have tried to their conditioning regiment. Flu-Cy although great conditioning for ASCT its proving dangerous for CARTs.
If it follows like every other biotech I've been in it will run up after news release of positive data and sell off after approval.
Well technically couldn't the final even has happened but the data is under review by the DMC. The company would still technically be blinded still.
Yes but it's still a distraction and they will still incur legal fees. at this point they may be best selling off the Ido and restructuring to just a infectious disease company,
In minimal disease they won't work especially in tumors that are relatively antigenically silent I,e PANC. Trial after trial have failed. Perhaps if we can figure out how to efficiently expand T cell clones in Vivo then maybe but until then I stand by my comment that cancer vaccines will fail and will especially fail in a minimal disease setting,
Starting to add a position here. Will do so gradually over the next 3-4 days. IMO enter on this weakness and forget you own these shares. Take a peak in Dec after ASH conference and you will be pleasantly surprised.
Yes I'm aware of VLP based vaccines and companies that have tried to use them before I.e. novavax. Still he same basic problem exists. You have to rely on the immune system to expand antigen specific cytotoxic T cells in Vivo. Not gonna happen. We've tested this multiple times using multiple different systems that latest of which is hyperacute vaccine.
Ok I'll bite. I always enjoy arguing with self proclaimed "experts" on message boards. Do tell me Mr Gene what comment that I posted was so ridiculous? It is a fact you can not have cytotoxic T cell expansion without the presence of antigens. Remember its an T Cell expansion is via an autocrine response that is at its core dependent on antigens.